Trial Profile
A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Alvine Pharmaceuticals
- 15 Oct 2014 New trial record